Literature DB >> 11143256

Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note.

M Levivier1, D Wikier, S Goldman, P David, T Metens, N Massager, M Gerosa, D Devriendt, F Desmedt, S Simon, P Van Houtte, J Brotchi.   

Abstract

The purpose of this study was to assess the use of positron emission tomography (PET) as a stereotactic planning modality for gamma knife radiosurgery (GKS). The authors developed and validated a technique for fiducial marker imaging, importation, and handling of PET data for integration into GammaPlan planning software. The clinical feasibility in applying this approach to a selected group of patients presenting with recurrent glial tumors or metastases was evaluated. Positron emission tomography data can be integrated into GammaPlan, allowing a high spatial accuracy, as validated using a phantom. Positron emission tomography data were successfully combined with magnetic resonance (MR) images to define the target volume for the radiosurgical treatment of patients with recurrent glioma or metastasis. This approach may contribute to optimizing target selection for infiltrating or ill-defined brain lesions. Because PET is also useful for the pretreatment and follow-up evaluation, the use of stereotactic PET in these patients can enable an accurate comparison of PET-based metabolic data with MR-based anatomical data. This could give a better understanding of the metabolic changes following radiosurgery. The ability to use PET data in GKS represents a crucial step toward further developments in radiosurgery, as this approach provides additional information that may open new perspectives for the optimization of the treatment of brain tumors.

Entities:  

Mesh:

Year:  2000        PMID: 11143256     DOI: 10.3171/jns.2000.93.supplement

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

Review 1.  PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques.

Authors:  Habib Zaidi; Issam El Naqa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

2.  Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors.

Authors:  Benoit Pirotte; Marc Levivier; Daniele Morelli; Patrick Van Bogaert; Dominique Detemmerman; Philippe David; Daniele Baleriaux; Jacques Brotchi; Serge Goldman
Journal:  Childs Nerv Syst       Date:  2004-12-10       Impact factor: 1.475

Review 3.  Stereotactic radiosurgery and interstitial brachytherapy for glial neoplasms.

Authors:  M W McDermott; M S Berger; Sandeep Kunwar; Andrew T Parsa; P K Sneed; David A Larson
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

4.  11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.

Authors:  B N T Tang; M Levivier; M Heureux; D Wikler; N Massager; D Devriendt; P David; N Dumarey; B Corvilain; S Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-15       Impact factor: 9.236

5.  Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study.

Authors:  K Miwa; J Shinoda; H Yano; A Okumura; T Iwama; T Nakashima; N Sakai
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

6.  PET imaging in the surgical management of pediatric brain tumors.

Authors:  Benoit Pirotte; Francesco Acerbi; Alphonse Lubansu; Serge Goldman; Jacques Brotchi; Marc Levivier
Journal:  Childs Nerv Syst       Date:  2007-03-14       Impact factor: 1.532

7.  Use of diffusion-weighted MRI to modify radiosurgery planning in brain metastases may reduce local recurrence.

Authors:  Rasheed Zakaria; Andreas Pomschar; Michael D Jenkinson; Jörg-Christian Tonn; Claus Belka; Birgit Ertl-Wagner; Maximilian Niyazi
Journal:  J Neurooncol       Date:  2016-11-14       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.